We review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti-\r\nVEGF antibodies, and also evaluating their outcomes. Intraocular injections of anti-VEGF drug are considered to be an effective\r\ntreatment for macular edema after retinal vein occlusion, however, recurrent/persistent edema is common. The recent reports\r\nmay lead to a shift in treatment paradigm for DME, from laser photocoagulation, to newer approaches using anti-VEGF drugs.\r\nThere have been several well-publicized prospective, randomized studies that demonstrated the efficacy of intravitreal injection of\r\nanti-VEGF drugs for patients with AMD. Adjuvant bevacizumab for neovascular glaucoma may prevent further PAS formation,\r\nand it is likely to open up a therapeutic window for a panretinal photocoagulation and trabeculectomy. Intravitreal injection of\r\nbevacizumab (IVB) results in a substantial decrease in bleeding from the retinal vessels or new vessels during a standard vitrectomy.\r\nIVB has also been reported to be effective for inducing the regression of new vessels in proliferative diabetic retinopathy. The use\r\nof bevacizumab in stage 4 or 5 retinopahty of permaturity (ROP) is to reduce the plus sign to help reduce hemorrhage during the\r\nsubsequent vitrectomy. Some authors reported cases of resolution of stage 4 A ROP after bevacizumab injection.
Loading....